Phio Pharmaceuticals Corp. entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply of its lead compound PH-762, a critical step in advancing its cutaneous carcinoma treatment program.
Key takeaways
Phio Pharmaceuticals entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply.
The agreement covers manufacturing of Phio's lead compound PH-762 for both clinical and commercial supply.
Phio's Phase 1b trial for PH-762 involved 22 patients across five dose-escalation cohorts with no dose-limiting toxicities or serious adverse events.
The trial reported a pathological response rate in cSCC of approximately 65% across all dosing cohorts, including 85% (6 of 7 patients) in the highest-dose cohort.
FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026.
Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027.